Canadian study tracks Real-World impact of kidney drug on Patients' lives

NCT ID NCT02925221

Completed Knowledge-focused Sponsor: Otsuka Canada Pharmaceutical Inc. Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 19, 2026 · Updated 19 times

Summary

This study followed 530 adults with autosomal dominant polycystic kidney disease (ADPKD) who were already prescribed tolvaptan (JINARC™) by their doctor. Researchers observed how the drug affected patients' quality of life, pain, and ability to work, as well as how long it took before they needed dialysis or a kidney transplant. The goal was to understand the real-world benefits and long-term outcomes of tolvaptan treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Edmonton, Alberta, Canada
Study site

London, Ontario, Canada
Study site

Ottawa, Ontario, Canada
Study site

Toronto, Ontario, Canada
Study site

Montreal, Quebec, Canada
Study site

Québec, Quebec, Canada

Conditions

Explore the condition pages connected to this study.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD